PT - JOURNAL ARTICLE AU - Ondigui, Juliette-Laure Ndzie AU - Goumkwa, Nadège Mafopa AU - Lobe, Cindy AU - Wandji, Brigitte AU - Awoumou, Patrick AU - Djivida, Prisca Voussou AU - Peyonga, Puinta AU - Atah, Solange Manju AU - Verbe, Vivian AU - Simo, Rachel Kamgaing AU - Moudourou, Sylvie Agnès AU - Gutierrez, Ana AU - Garcia, Rosi AU - Fernandez, Isabelle AU - Riwom Essama, Sara Honorine AU - Mbu, Robinson AU - Torimiro, Judith TI - High prevalence and risk factors of transmission of hepatitis delta virus in pregnant women in the Center Region of Cameroon AID - 10.1101/2023.06.08.23291160 DP - 2023 Jan 01 TA - medRxiv PG - 2023.06.08.23291160 4099 - http://medrxiv.org/content/early/2023/06/12/2023.06.08.23291160.short 4100 - http://medrxiv.org/content/early/2023/06/12/2023.06.08.23291160.full AB - Background Hepatitis B virus (HBV) and hepatitis delta virus (HDV) co-infection has been described as the most severe form of viral hepatitis, and both can be co-transmitted from mother-to-child. A seroprevalence of 4.0% of HDV infection was reported in pregnant women in Yaoundé, and 11.9% in the general population in Cameroon. Our objective was to describe the rate of HDV infection in pregnant women and to determine risk factors associated with mother-to-child transmission of HDV.Materials and Methods A cross-sectional, descriptive study was conducted from January 2019 to July 2022 among pregnant women attending antenatal contacts in seven health structures in the Centre Region of Cameroon. A consecutive sampling (non-probability sampling) was used to select only women of age over 21 years, who gave a written informed consent. Following an informed consent, an open-ended questionnaire was used for a Knowledge, Attitude and Practice (KAP) survey of these women, and their blood specimens collected and were screened for HBsAg, anti-HIV and anti-HCV antibodies by rapid tests and ELISA. HBsAg-positive samples were further screened for HBeAg, anti-HDV, anti-HBs, and anti HBc antibodies by ELISA, and plasma HDV RNA load measured by RT-qPCR.Results Of 1992 pregnant women, a rate of 6.7% of HBsAg (134/1992) with highest rate in the rural areas, and 3.9% of hepatitis vaccination rate were recorded. Of 134, 44 (32.3%) were anti-HDV antibody-positive, and 47.6% had detectable RNA viraemia. Two women of 44 anti-HDV-positive cases (4.5%) were co-infected with HBV and HCV, while 5 (11.4%) with HIV and HBV. Multiple deliveries, the presence of tattoos and/or scarifications were significantly statistically associated with the presence of anti-HDV antibodies. Of note, 80% of women with negative HBeAg and positive anti-HBe serological profile, had plasma HDV RNA load of more than log 3.25 (>10.000 copies/ml).Conclusion These results show an intermediate rate of HDV infection among pregnant women with high level of HDV RNA viremia, which suggest an increased risk of vertical and horizontal co-transmission of HDV.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received specific funding from PI Institution and Award to PI.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The National Ethics Committee for Human Health Research in Cameroon (N° 2018/06/1150/L/CNERSH/SP)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.